Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Revenue for 15 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 16.19% to $33.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $129.4 million, a 29.95% increase, with the full-year FY2025 number at $129.4 million, up 29.95% from a year prior.
  • Revenue was $33.8 million for Q4 2025 at Niagen Bioscience, roughly flat from $34.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $34.0 million in Q3 2025 to a low of $14.7 million in Q1 2021.
  • A 5-year average of $22.6 million and a median of $21.1 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: fell 5.46% in 2022, then soared 37.59% in 2025.
  • Niagen Bioscience's Revenue stood at $17.8 million in 2021, then grew by 18.23% to $21.0 million in 2022, then rose by 0.95% to $21.2 million in 2023, then surged by 37.41% to $29.1 million in 2024, then increased by 16.19% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Revenue are $33.8 million (Q4 2025), $34.0 million (Q3 2025), and $31.1 million (Q2 2025).